Citation Impact
Citing Papers
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
2008 Standout
Preventive therapy for breast cancer: a consensus statement
2011
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
2004
The clinician’s guide to prevention and treatment of osteoporosis
2022
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2008
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Is Radiographic Vertebral Fracture a Risk Factor for Mortality?
2007
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>
2003 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
Thiazolidinediones
2004 Standout
Mammographic Density and the Risk and Detection of Breast Cancer
2007 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Contributions of estrogen to ER-negative breast tumor growth
2006
Design and methods of the Raloxifene Use for The Heart (RUTH) study
2001
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
2002
Osteoporosis
2006
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Use of doping agents, particularly anabolic steroids, in sports and society
2008 Standout
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
2002 Standout
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
2001 StandoutNobel
Is dehydroepiandrosterone a hormone?
2005
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Primary Care for Survivors of Breast Cancer
2000
Endometriosis
2009 Standout
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
2006
Preventing fractures in elderly people
2003
Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis
2013
Intervention thresholds for osteoporosis in the UK
2004
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2005
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
2011
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
Intervention thresholds for osteoporosis
2002
Osteoporosis: now and the future
2011 Standout
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures
2001
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
2004
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Treatment of postmenopausal osteoporosis
2002
Epidemiology of breast cancer
2001
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
2005
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Contribution of Raloxifene and Calcium and Vitamin D3Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women
2003
Uterine fibroids
2001 Standout
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
2014
Endocrine-responsive breast cancer and strategies for combating resistance
2002
Assessing the Risk of Breast Cancer
2000
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Osteoclast differentiation and activation
2003 StandoutNature
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
2006
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Estrogen plus Progestin and the Risk of Coronary Heart Disease
2003 Standout
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
2005
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
2004 Standout
At what hip fracture risk is it cost-effective to treat?
2006
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
2004
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
Cancer control in women. Update 2003
2003
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
2004
Breast cancer risk assessment models
2002
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
2004
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
2010
Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study
2000
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
2009 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Prevention of falls and consequent injuries in elderly people
2005 Standout
Roles of PPARs in health and disease
2000 StandoutNature
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective
2004
Oestrogen exposure and breast cancer risk
2003
Cancer of the Ovary
2004 Standout
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
2005
Fluorine in medicinal chemistry
2007 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6-Month Double-Blind Placebo-Controlled Trial
2005
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
2010
Bone Resorption by Osteoclasts
2000 StandoutScience
Selective Estrogen Receptor Modulators
2004
Glass Formation of a Coordination Polymer Crystal for Enhanced Proton Conductivity and Material Flexibility
2016 StandoutNobel
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
2008
A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator
2007
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions
2003
Noncardiovascular disease outcomes during 6.8 years of hormone therapy. heart and estrogen/progestin replacement study follow-up (HERS II)
2002
Weight Loss in Breast Cancer Patient Management
2002
Cancer Genome Landscapes
2013 StandoutScience
The Epidemiology of Venous Thromboembolism
2003 Standout
Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies
2002 Standout
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
2002 Standout
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
1999
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
2005
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma
2000
Therapeutic Approaches to Bone Diseases
2000 Science
Bone Loss and Bone Size After Menopause
2004
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
Works of Stephen Eckert being referenced
Digitized Mammography: a Clinical Trial of Postmenopausal Women Randomly Assigned to Receive Raloxifene, Estrogen, or Placebo
2001
Geographic Differences in Bone Turnover: Data from a Multinational Study in Healthy Postmenopausal Women
1998
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
2001
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
1999
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
2000
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
2000
Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants
2001